Befiradol

DB19033InvestigationalSmall molecule

Befiradol is under investigation in clinical trial NCT05148884 (Study to Assess the Safety, Tolerability and Preliminary Efficacy of NLX-112 Versus Placebo in L-dopa-induced Dyskinesia).

Mechanism: Pharmacologically active on 5-hydroxytryptamine receptor 1A
Curator reviewed
Formula / weight: C₂₀H₂₂ClF₂N₃O · 393.86 g/mol (avg)
Also known as: (2E)-2-butenedioate · (3-chloro-4-fluorophenyl)(4-fluoro-4-((((5-methylpyridin-2-yl)methyl)amino)methyl)piperidin-1-yl)methanone · 4-piperidinemethanamine
Code names: F-13640 · NLX-112

Resolves to

Compound

UNIIRAT9OHA1YHCAS208110-64-9ChEMBLCHEMBL45305

Structure

InChIKeyPKZXLMVXBZICTF-UHFFFAOYSA-NSMILESCC1=CC=C(CNCC2(F)CCN(CC2)C(=O)C2=CC=C(F)C(Cl)=C2)N=C1

Targets

P08908HTR1A

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

2Clinical trialsPhase, status and sponsor resolved per trial

5+ReferencesStructured and connected to the statements they support

Which drugs share a target with Befiradol, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account